Study S000697

A 52-Week, Open-Label, Long-Term Safety Study of LY2189265 in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01468181
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 394
Start: 2011-11
Primary completion: 2013-12
Lead sponsor: Eli Lilly and Company
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:LY2189265; DRUG:Sulfonylureas (SU); DRUG:Biguanides (BG); DRUG:alpha-glucosidase inhibitor (a-GI); DRUG:Thiazolidinedione (TZD); DRUG:Glinides
Results posted: TRUE
Secondary identifiers: OTHER:H9X-JE-GBDQ

Registered primary outcomes

Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) [Baseline through 52 Weeks]
Percentage of Participants With Hypoglycemic Episodes [Baseline through 52 Weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.